Compare IDEXX Laboratories, Inc. (IDXX) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs The Coca-Cola Co K — how do they compare? IDEXX Laboratories, Inc. trades at $519.93 (market cap $40.43B), while The Coca-Cola Co K trades at $88.17 (market cap $377.63B). The key difference: The Coca-Cola Co K is far larger — about 9.3× IDEXX Laboratories, Inc.'s market cap, and The Coca-Cola Co K pays a 2.42% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and The Coca-Cola Co K for 154 Days on average.
| IDXX | KO | |
|---|---|---|
Market Cap | $40.43B | $377.63B |
Volume | 692,164 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $91.99 |
52-Week Low | $504.70 | $66.37 |
Typical Hold Time | 46 Days | 154 Days |
Enterprise Value | $41.32B | $404.81B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Coca-Cola (KO) trades at $87.97, up 2.51% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong profitability with a 28.56% net income margin and a 44.23% ROE for 2025. Analyst consensus is a Buy with a $95.75 price target, and institutional buying activity is evident in recent news. The stock is positioned near key resistance at $88, with support at $87.
The outlook for KO is positive, driven by consistent earnings performance and a strong dividend history, but risks include high valuation multiples and regional demand volatility. The stock offers stability with growth potential, though investors should monitor debt levels and competitive pressures in the beverage industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
